Tables

2.1 Biotechnology research groups in Brazil, 2002–04 16
2.2 Estimated R&D expenditures in pharmaceutical industry by country, 1990–2004 31
2.3 Regional share of worldwide clinical trial sites 32
2.4 R&D expenditures abroad by US pharmaceutical MNCs (PhRMA members), 2005 33
2.5 Established enterprises in health biotechnology, Belo Horizonte, 1999 35
2.6 Incubated enterprise of Biominas Foundation, 1999 36
2.7 Biobrás collaborative and partnership relations and network for human recombinant insulin development, 1991–98 41
2.8 Technological progress of Biobrás in insulin production 42
2.9 Importance attributed to sources of information for innovation by micro and small firms in the local biotech system of Belo Horizonte, 2008 48
2.10 Importance attributed to forms of cooperation by micro and small firms in the local biotech system of Belo Horizonte 50
2.11 Utilization by firms of government innovation programmes, 2008 51
5.1 Biotechnology R&D at universities 114
5.2 Biotechnology research capacities at the National Research Institutes 115
A5.1 List of institutions contacted during the study 138
8.1 The development of China’s domestic biological industry base in 2007 188
8.2 The general situation of invention patent application and authorization for Chinese biotechnology between 1997 and 2006 192
9.1 Public biotechnology budgets in the period 2002–05 227
9.2 Allocation of biotechnology funding between 2002 and 2005 to ten different policy goals 228
9.3 Thematic priorities of biotechnology funding in terms of budget allocation 229
9.4 Biotechnology industry characteristics 240
Biotechnology and innovation systems

10.1 Number of companies and employment in Swedish life science industry, 2006 248
10.2 Selected Danish large and old companies within life science 250
10.3 Number of companies and employment in Danish life science industry, 2006 251
10.4 Typology of biotechnology policies for Denmark and Sweden, 2004 262
11.1 Main institutional actors and selected research themes in Latvia’s biotechnology landscape: development chronology 282
11.2 Major funding sources for the biotechnology sector in Latvia 295
12.1 Indicators for the appropriation of biotechnology in Germany 317
12.2 Non-university research organizations 320
12.3 Typology of biotechnology policies 325
13.1 Funding of biotechnology R&D through the federal programme ‘R&D in priority areas of Russia’s S&T complex development in 2007–2012’ out of the RF federal budget for 2007 336
13.2 Major research areas in which Russian R&D organizations are active, and how they compare with top international results 338
13.3 Breakdown of enterprises manufacturing products with the help of biotechnologies 344
13.4 Effects of biotechnology implementation 348
13.5 Socio-economic effects of critical technologies 349